Table 1.
Epidemiologic and clinical characteristics of the patients included in the study
| Variables | All patients (N = 42) | |
|---|---|---|
| Socio-demographic features | ||
| Age, years, mean (SD) | 39.52 (14.48) | |
| Time since first onset, years mean (SD) | 8.28 (10.73) | |
| Sex Male, % (N) | 40.47% (17/42) | |
| Sex Female, % (N) | 59.52% (25/42) | |
| Time since last episode of AA, years, mean (SD) | 3.32 (4.16) | |
| Previous treatments, % (N) | ||
| topical steroids | 76% (32/42) | |
| intralesional injections | 45.2% (19/42) | |
| topical calcineurin inhibitors | 14.2% (6/42) | |
| DPCP | 14.2% (6/42) | |
| Anthralin | 9.5% (4/42) | |
| systemic cortisone | 71% (30/42) | |
| cyclosporine | 52% (22/42) | |
| JAKi | 4.7% (2/42) | |
| PRP | 9.5% (4/42) | |
| hydroxychloroquine | 4.7% (2/42) | |
| Comorbidities, % (N) | ||
| thyroid disease | 38% (16/42) | |
| myasthenia gravis | 4.7% (2/42) | |
| diabetes mellitus | 4.7% (2/42) | |
| vitiligo | 2% (1/42) | |
| hypertension | 4.7% (2/42) | |
| asthma | 2% (1/42) | |
| rheumatoid arthritis | 2% (1/42) | |
| Severity of the disease | ||
| Basal SALT score mean (SD) | 80.21 (24.09) | |
| Current SALT score mean (SD) | 43.27 (39.44) | |
| Treatment characteristics | ||
| Baricitinib | Tofacitinib | |
| Mean treatment time (months) | 2.7 | 11.7 |
| Maintenance dose (mg/day) | 4mg/day | 10mg/day (17/22) |
| 20mg/day (5/22) | ||
Jaki=Janus kinase inhibitor; PRP=Platelet Rich Plasma; SALT = Severity of Alopecia Tool; SD=Standard deviation;